ライフサイエンスコーパス: anal

1 6 (P < .001), weekly alcohol use (P = .015), anal touching during sex (P = .045), recent anal sex (P

2 ng paraffin-embedded tumor biopsies from 143 anal carcinomas.

3 ncident anogenital cancers (273 cervical, 24 anal, 67 vulvar, 12 vaginal, and 24 penile cancers) with

4 pational exposure of healthcare workers; (5) anal cancer screening among men who have sex with men (M

5 s sarcoma (OR, 48.2; 95% CI, 22.0 to 105.6), anal (OR, 15.5; 95% CI, 11.0 to 21.9), and penile cancer

6 were symptomatic with anal bleeding (78 %), anal/perianal pain (63 %), weight loss (31 %) and foreig

7 HPV (any type) was detected in 742 (71.8%) anal specimens and 101 (9.8%) oral specimens.

8 , 4.5% and 0.7%; lung cancer, 3.4% and 2.8%; anal cancer, 1.5% and 0.05%; colorectal cancer, 1.0% and

9 Abnormal anal cytology and HPV-16 infection performed best as a s

10 ; 208 women underwent HRA following abnormal anal cytology.

11 Thirty-nine percent had abnormal anal cytology on initial screen and 15% on secondary scr

12 The incidence of abnormal anal cytology findings was high and more likely to devel

13 31 (81%) AGWs with high-grade lesions or an anal carcinoma were p16INK4a-positive.

14 ial (37%), breast (31%), cervical (29%), and anal cancer (27%).

15 95% confidence interval [CI], 1.1-16.4) and anal HPV-16 infection (OR, 16.1; 95% CI, 5.4-48.3) was a

16 brow hairs (60.9%), oral mucosa (35.6%), and anal mucosa (33.3%).

17 al adenocarcinoma, oropharyngeal cancer, and anal cancer.

18 We present findings of cervical and anal HPV and cytologic tests at baseline in the EVVA coh

19 e seen at 4-month intervals for cervical and anal HPV testing.

20 Cervical and anal specimens collected semiannually were tested using

21 oracic, metathoracic, abdominal, dermal, and anal glands, are revealing unforeseen trophic relationsh

22 jection (abdominal distention, diarrhea, and anal mucosa inflammation) were observed three weeks afte

23 E6 antibodies, apart from anti-HPV58 E6 and anal cancer (OR, 6.8; 95% CI, 1.4 to 33.1).

24 r pattern, associated with gas expulsion and anal sphincter relaxation, inferred to be associated wit

25 Genital and anal specimens were available for 1348 MSW participants,

26 squamous intraepithelial lesions (HSIL) and anal cancer (AC) compared with HIV-uninfected women.

27 those that contribute to posterior lobe and anal plate divergence.

28 hology of the claspers, posterior lobes, and anal plates exhibit striking differences between Drosoph

29 ositive species that colonizes the nares and anal mucosa of healthy dogs and cats.

30 o 90% of anal intraepithelial neoplasias and anal cancers.

31 act via pathways independent of the oral and anal routes.

32 genital skin swabs, oral rinse samples, and anal swabs.

33 Self-reported anal sex and anal symptoms were independently associated with anorect

34 Among 834 without HIV infection, any anal HPV was detected in 69.4% and any oral HPV in 8.4%,

35 As anal cancer is potentially preventable, these important

36 ession levels was observed in HIV-associated anal SCCs (fold change, 12.69; P < .001).

37 ty of patients (63 [69%]) were asymptomatic (anal pain, 11 [12%]; bleeding, 14 [15%]; and pruritus, 1

38 al malformations comprising choanal atresia, anal abnormalities, post-axial polydactyly, heart defect

39 ith suppressed HIV-1 RNA viral load for both anal and vaginal sex.

40 e incidence of precursor lesions detected by anal cytology.

41 study strengthens evidence that lung cancer, anal cancer, and myeloma are diagnosed at modestly young

42 g men who have sex with men (MSM) and causes anal cancer.

43 iruses are the causative agents of cervical, anal as well as many oropharyngeal cancers.

44 eviews, cervical/anal cytologic and cervical/anal HPV testing for 2 years.

45 uded questionnaires, chart reviews, cervical/anal cytologic and cervical/anal HPV testing for 2 years

46 ed to as an "anus" by Main [18], and coined "anal pores" by Hyman [19]-contradictory reports, particu

47 tract infection caused by Escherichia coli, anal lymphogranuloma venereum infection, and a positive

48 anal HPV infection using clinician-collected anal swabs for HPV DNA testing obtained during a 1-year

49 Self-collected anal swab and oral rinse specimens were tested for HPV D

50 In contrast, commercial anal sex with male (11.9% to 7.1%, p < 0.001) and drug u

51 use as well as condom use during commercial anal sex (46.5% to 55.0%, p < 0.001) were increasing.

52 ted standardized incidence ratios to compare anal cancer incidence in people with HIV infection with

53 he upper 95% confidence limit for condomless anal sex was 0.71 per 100 couple-years of follow-up.

54 ine and tenofovir for MSM who had condomless anal sexual intercourse in the previous 3 months, a nega

55 n and transgender women reporting condomless anal intercourse with >/=1 HIV-infected or unknown-seros

56 significantly more serodiscordant condomless anal intercourse, bacterial sexually transmitted infecti

57 The presentation of painful defecation, anal fissures, and macroscopic blood in stools was highl

58 le and clinically relevant methods to detect anal cancer precursors.

59 provided the highest accuracy for detecting anal precancer.

60 seven of 24 individuals) who later developed anal cancer compared with 0.6% of controls (four of 718

61 life years, and lifetime risk of developing anal cancer.

62 therapy (with azithromycin or doxycycline), anal, vaginal, or urine samples were self-collected duri

63 anal sex (P = .04), and no condom use during anal sex (P = .04) were associated with HPV-16 persisten

64 We studied the Caenorhabditis elegans anal depressor development in larval males and hermaphro

65 ulation, used Poisson regression to evaluate anal cancer incidence among subgroups of people with HIV

66 ometry and imaging are useful for evaluating anal and pelvic floor structure and function.

67 mine the role of Wnt pathway in the external anal sphincter (EAS) injury-related fibrosis and muscle

68 presentation, physical examination findings, anal Papanicolaou (Pap) smear findings.

69 Imaging modalities such as fistulography, anal endosonography, perineal sonography, magnetic reson

70 For anal, colorectal, and liver cancer, increasing cumulativ

71 nal cancer, 6.68 (95% CI, 3.64 to 12.25) for anal intraepithelial neoplasia grade 3, 4.97 (95% CI, 3.

72 te ratios of 3.85 (95% CI, 2.32 to 6.37) for anal cancer, 6.68 (95% CI, 3.64 to 12.25) for anal intra

73 sidered when selecting the best approach for anal cancer screening programs.

74 tertiary dermatological referral center for anal cancer screening.

75 ponse evaluation after chemoradiotherapy for anal cancer.

76 87 patients treated by chemoradiotherapy for anal squamous cell carcinoma between October 2007 and Oc

77 mavirus (HPV) infection and risk factors for anal high-risk (HR) HPV infection in human immunodeficie

78 Here we report outcomes and risk factors for anal HSIL following implementation of universal AC scree

79 lished on prevalence of and risk factors for anal precancer and potential screening strategies in thi

80 Guidelines for anal cancer recommend assessment of response at 6-12 wee

81 with increased cancer-specific mortality for anal cancer, Hodgkin lymphoma, or diffuse large B-cell l

82 23.5 +/- 4.1 years) who tested positive for anal HPV were followed for a mean of 84.5 +/- 44.9 month

83 to use in clinical research and practice for anal cancer since no questionnaire specific for anal can

84 with patients in general, and profoundly for anal sex.

85 used to record adverse events using PROs for anal cancer.

86 us (HIV)-infected women are at high risk for anal cancer, few data have been published on prevalence

87 ingly advocated as a method of screening for anal dysplasia in high-risk patients.

88 l cancer since no questionnaire specific for anal cancer has been developed.

89 detection is a potentially relevant tool for anal cancer screening.

90 samples and 78.6% (95% CI: 69.4-87.7%) from anal samples; 2.7% (95% CI: 0.7-4.7%) for Epstein-Barr v

91 distal tumour border of less than 12 cm from anal verge.

92 abdominal posterior dissection to <4 cm from anal verge.

93 e anterior region is more likely to generate anal sphincter contraction than FHL contraction.

94 s are at increased risk of having high-grade anal dysplasia.

95 h men (MSM) who have a history of high-grade anal intraepithelial neoplasia (HGAIN) was associated wi

96 High-grade anal intraepithelial neoplasia or worse (HG-AIN+) was di

97 IM treatments, HM treatment produced greater anal pressure.

98 At baseline, 75% had anal HPV, 51% had anal HR-HPV, 50% had cervical HPV, and 29% had cervical

99 At baseline, 75% had anal HPV, 51% had anal HR-HPV, 50% had cervical HPV, and

100 other men who have sex with men who had had anal intercourse without a condom in the previous 90 day

101 e of PVOD in the French population that have anal cancer is 3.9 of 1000 patients, which is much highe

102 tone and is important for maintaining a high anal pressure while tone in the rectum is less.

103 develops tone important for maintaining high anal pressure and continence.

104 d oral mucosa (9.2%), and HPV-76 (beta-3) in anal mucosa (14.9%).

105 To evaluate the performance of HPV assays in anal samples, we compared the cobas HPV test (cobas) to

106 gations of PD-1/PD-L1 checkpoint blockade in anal SCC, irrespective of patient HIV status.

107 that cobas can be used for HPV detection in anal cytology specimens.

108 on of IC infiltration or PD-L1 expression in anal SCC.

109 t for the detection of most HPV genotypes in anal samples.

110 ybribio GenoArray (GA) for genotyping HPV in anal samples, against the reference standard Roche Linea

111 he EAS resulted in significant impairment in anal canal pressure and EAS muscle L-T function.

112 consequence of staging misclassification in anal cancer that we have termed reduced prognostic discr

113 IC subsets, and gene expression profiles in anal SCCs from HIV-positive vs HIV-negative patients.

114 -HPV infections, consistent with its role in anal cancer.

115 ive of ongoing viral replication, more so in anal HSILs.

116 MSM) is closely related to the role taken in anal sex (insertive, receptive or both), but little is k

117 was greater in oral and skin samples than in anal samples.

118 ndings demonstrate an immune-reactive TME in anal SCCs from HIV-positive patients and support clinica

119 local tumor immune microenvironment (TME) in anal SCCs from HIV-positive and HIV-negative patients.

120 The results were compared with HPV types in anal swabs.

121 and clinician reporting instruments used in anal cancer trials including radiation treatment.

122 Routine clinical data included anal and cervical cytology, demographic/behavioral data,

123 an papillomavirus-related cancers, including anal cancer (HR, 2.77; 95% CI, 1.29-5.96) and female gen

124 lts Among 447,953 people with HIV infection, anal cancer incidence was much higher than in the genera

125 ex to 14.8% in men reporting >/= 4 insertive anal sex partners (P = .014).

126 Having one partner and insertive anal sex without a condom had the highest NNTs (100 and

127 rom 3.7% in men reporting no prior insertive anal sex to 14.8% in men reporting >/= 4 insertive anal

128 CK) in the smooth muscle cells from internal anal sphincter (IAS-SMCs) abolishes basal tone, impairin

129 in the regulation of basal tone in internal anal sphincter (IAS).

130 induced significant contraction of internal anal sphincter pressure over 12h after injection, and th

131 The internal anal sphincter (IAS) develops tone and is important for

132 m underlying tone generation in the internal anal sphincter (IAS) is controversial.

133 KEY POINTS: The internal anal sphincter develops tone important for maintaining h

134 We studied 3 patients with focal intra-anal tissue high-grade squamous intraepithelial lesions

135 sia in 31 cases (81%), and areas of invasive anal carcinoma in 1 (3%) case.

136 In both sexes, the larval anal depressor muscle is used for defecation behavior.

137 ids were confirmed (cleft palate, cleft lip, anal atresia, and hypospadias).

138 ists were found for spina bifida, cleft lip, anal atresia, severe congenital heart defects in general

139 -risk HPV was associated with number of male anal sex partners and inversely associated with number o

140 The male anal depressor begins to change in the L3 stage, first b

141 re over 12h after injection, and the maximum anal pressure was obtained between 5 and 6h.

142 e compounds present in 'pure' versus 'mixed' anal-gland secretions ('paste') of adult meerkats (Suric

143 Most anal cancers are attributable to persistent human papill

144 Most anal HR-HPV types detected at 6 months (57%-93%) were pe

145 previously or were heterosexual reporting no anal intercourse in the past year, and 1861 did not prov

146 HSIL was found in 26% and 18% of anal biopsies following initial and secondary screening,

147 er, the detection of HPV DNA in up to 76% of anal samples warrants further evaluation of its clinical

148 ncer, as HPV DNA is detected in up to 90% of anal intraepithelial neoplasias and anal cancers.

149 assess the risk of sequential acquisition of anal human papillomavirus (HPV) infection following a ty

150 than did control patients (mean arc angle of anal canal involved, 220 degrees vs 60 degrees ; P < .00

151 (HIV)-infected women have a higher burden of anal high-grade squamous intraepithelial lesions (HSIL)

152 In the USA, more than 7200 new cases of anal cancer were diagnosed in 2014 with incidence rising

153 A combination of anal cytology and HPV genotyping provided the highest ac

154 ination may be useful for early detection of anal cancer in these populations.

155 s but low specificities for the detection of anal intraepithelial neoplasia grade 2/3 (AIN2/3) in thi

156 ity is relatively common before diagnosis of anal cancer but rare for other HPV-related anogenital ca

157 Duration of anal HPV did not differ for MSOM and MSWM and was a medi

158 at least 2,300 IU of HCV for the duration of anal intercourse.

159 There are few published estimates of anal human papillomavirus (HPV) infection rates among yo

160 good accuracy in posttreatment evaluation of anal cancer and has a relevant impact on patient managem

161 e in people with AIDS, with the exception of anal and lung cancers.

162 g clinical symptoms and physical findings of anal carcinoma.

163 Findings of anal cytologic tests were abnormal for 37% of women.

164 ective was to examine the natural history of anal HPV in heterosexual women.

165 lvic examination, regardless of a history of anal intercourse, were screened for rectal C. trachomati

166 224 men and 175 women reporting a history of anal receptive sexual intercourse.

167 Groups with high cumulative incidence of anal cancer may benefit from screening.

168 o -1.86; P < .001), whereas the incidence of anal cancer significantly increased (APC, 4.42; 95% CI,

169 s, and estimated the cumulative incidence of anal cancer to measure absolute risk.

170 Incidence of anal carcinoma (AC) is increasing and timely diagnosis i

171 With the gradual increase of anal cancer rates, there is a growing need to establish

172 The majority of anal HPV infections cleared within 3 years.

173 calibrated using a natural history model of anal carcinogenesis.

174 known about the type-specific prevalence of anal human papillomavirus (HPV) infection and risk facto

175 Given high rates of anal disease, we investigated the natural history of hig

176 significantly lower incidence rate ratios of anal infection with HPV6/11/16/18 (0.4; 95% CI, .2-.7).

177 rticipants with negative baseline results of anal cytology, 37% developed abnormal cytology findings

178 ssary to identify men at the highest risk of anal cancer among those infected with high-risk HPV.

179 ent for HGAIN decreased the lifetime risk of anal cancer by 63% compared with no vaccination.

180 The risk of anal cancer due to high-risk human papillomavirus (HR-HP

181 with HIV infection have an elevated risk of anal cancer.

182 vaccination and decrease in lifetime risk of anal cancer.

183 Sequential risk of anal HPV infection was assessed using hazard ratios (HRs

184 A cross-sectional study of anal and cervical HPV infection was nested within a gyne

185 icant role during posttreatment follow-up of anal cancer.

186 eased risk for HG-AIN+ and should be offered anal cancer screening.

187 We report the case of a 66-year-old anal cancer female patient presenting with an asymptomat

188 We constructed a Markov model based on anal histology in HIV-positive MSM comparing qHPV vaccin

189 fected women reporting condomless vaginal or anal intercourse with at least 1 man with HIV infection

190 subject, we measured exhaled H2 and CH4, oro-anal transit time, and the severity of psychological and

191 However, patients with anal pain, anal lesions, and other high-risk factors are at increas

192 including cervical, vulvar, vaginal, penile, anal, and head-and-neck cancers.

193 and arcualia, W-shaped myomeres, and a post-anal tail.

194 subtotal colectomies (19%), 134 ileal pouch-anal anastomoses (21%), 23 segmental colectomies (8%), a

195 ter experience of transabdominal ileal pouch-anal anastomoses (IPAA) redo surgery for a failed initia

196 stomy, and 1172 (47.3%) received ileal pouch-anal anastomoses.

197 restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) substantially reduces the risk o

198 Pouchitis is common after ileal pouch-anal anastomosis (IPAA) surgery for ulcerative colitis (

199 re surgical outcome of transanal ileal pouch-anal anastomosis (ta-IPAA) with transabdominal minimal i

200 Although ileal pouch-anal anastomosis is recommended after colectomy for UC,

201 ery among patients who underwent ileal pouch-anal anastomosis was associated with higher 90-day posto

202 undergoing proctocolectomy with ileal pouch-anal anastomosis.

203 mbined total proctocolectomy and ileal pouch-anal anastomosis.

204 analysis, factors associated with prevalent anal HR-HPV infection were CD4(+)count <350/muL (odds ra

205 than 50% of patients with breast, prostate, anal, hepatocellular, colorectal, and cervical cancer ex

206 anal touching during sex (P = .045), recent anal sex (P = .04), and no condom use during anal sex (P

207 ex to 47.3% in men reporting >/= 4 receptive anal sex partners (P < .001).A similar pattern was also

208 RG-TFV rectal gel before and after receptive anal intercourse (RAI; or at least twice weekly in the e

209 schooling, who reported non-condom receptive anal intercourse, who had more sexual partners, and who

210 r among those reporting condomless receptive anal intercourse (416/519 [81%] vs 809/1084 [75%], p=0.0

211 arly Test (SDET) score: condomless receptive anal intercourse (CRAI) with an HIV-positive MSM (3 poin

212 e more likely to report condomless receptive anal sex in the prior 12 months (OR 2.44, 95% CI 2.05-2.

213 When adjusted for age, condomless receptive anal sex, depression, interpersonal stigma, law enforcem

214 eraction of gender with condomless receptive anal sex, the odds of HIV infection for transgender wome

215 l rectal screening of men who have receptive anal intercourse for Neisseria gonorrhoeae (GC) and Chla

216 The number of lifetime male receptive anal sex partners was significantly associated with HPV

217 teria for screening nor history of receptive anal sex was significantly associated with HSIL.

218 om 10.0% in men reporting no prior receptive anal sex to 47.3% in men reporting >/= 4 receptive anal

219 M and transgender women who report receptive anal intercourse without a condom, even if they perceive

220 roportion of individuals reporting receptive anal intercourse decreased (p=0.004).

221 d transgender women self-reporting receptive anal intercourse without a condom (NNT 36), cocaine use

222 uently reported transactional sex, receptive anal intercourse without a condom, or more than five par

223 -induced conversion (RT-QuIC) assay of recto-anal mucosa-associated lymphoid tissue (RAMALT) biopsy s

224 ed conversion (RT-QuIC) assay by using recto-anal mucosa-associated lymphoid tissue (RAMALT) biopsy s

225 This review summarizes clinically relevant anal sphincter anatomy, imaging methods, classification

226 = 185) of women had an indication (reported anal sex or symptoms), 72.5% (n = 689) did not have an i

227 Self-reported anal sex and anal symptoms were independently associated

228 Testing on indication of self-reported anal sex or symptoms is used to manage anorectal Chlamyd

229 eedles, resulting in the increase of resting anal sphincter pressure.

230 The resting anal sphincter pressure in response to various drug dose

231 nvestigated the natural history of high-risk anal human papillomavirus (HPV) among a multinational gr

232 Data are insufficient to recommend routine anal cancer screening with anal cytology in persons livi

233 A cross-sectional anal screening study was nested in a gynecological cohor

234 rearm skin) than across the 2 mucosal sites (anal and oral mucosa, 6.9%).

235 ed incidence and prevalence of type-specific anal HPV infection using clinician-collected anal swabs

236 ntly higher risk of sequential type-specific anal HPV infections was observed for any of the 9 types

237 a higher risk of a subsequent type-specific anal infection.

238 All patients displayed squamous anal cancer and were treated with MMC alone or MMC plus

239 ad a significantly higher risk of subsequent anal HPV 16 infections (HR, 4.63; 95% confidence interva

240 L contraction is associated with synergistic anal sphincter contraction, but voluntary anal sphincter

241 Multivariable analysis suggested that anal pain was independently associated with high-grade d

242 The anal cancer precursor, high-grade squamous intraepitheli

243 hallucis longus (FHL, a toe flexor) and the anal sphincter, as a model that we show to be well suite

244 colitis extending more than 15 cm beyond the anal verge (with a total Mayo score >/=6 and a Mayo endo

245 V-16 was the most prevalent type in both the anal canal (13.2% of women) and the cervix (5.1%).

246 ectal tissues collected up to 30 cm from the anal margin were all high at 2 hours, demonstrating rapi

247 , 1.5-9.6), tumors less than 4.0 cm from the anal verge (OR = 3.4; 95% CI, 1.3-8.8), and anterior tum

248 es, patients with a tumour 10-15 cm from the anal verge had improved disease-free survival (0.59, 0.4

249 fit patients with a tumour 10-15 cm from the anal verge in terms of disease-free survival and distant

250 ctal cancer, with a median distance from the anal verge of 5.0 cm.

251 ents with low rectal cancer (< 6 cm from the anal verge) suitable for sphincter preservation were ran

252 ients with very low tumors (</=4 cm from the anal verge), no significant difference in the local recu

253 rectal cancer located within 15 cm from the anal verge, followed by surgery.

254 ts with adenocarcinoma 6 cm or less from the anal verge.

255 ctal adenocarcinoma less than 15 cm from the anal verge.

256 astomotic height was 3.5 +/- 1.9 cm from the anal verge.

257 e distal rectum, approximately 5 cm from the anal verge.

258 HR-HPV types were detected in the anal canal in 148 women (47.6%) and in the cervix in 82

259 ce of HR-HPV types, including HPV-16, in the anal canal of HIV-positive women is concerning.

260 To address when the changes occur in the anal depressor, we used YFP:actin to monitor, and mutant

261 liver a phenylephrine (PE) solution into the anal sphincter muscle as a method for treating fecal inc

262 Squamous cell carcinoma of the anal canal (SCCA) is a rare malignancy associated with i

263 Purpose Squamous cell carcinoma of the anal canal (SCCAC) is characterized by high locoregional

264 Purpose Squamous cell carcinoma of the anal canal (SCCAC) is characterized by high locoregional

265 Carcinomas of the anal canal are strongly associated with the human papill

266 s with AJCC stages I to III carcinoma of the anal canal.

267 ncer (AJCC) stages I to III carcinoma of the anal canal.

268 y steps in the dimorphic re-sculpting of the anal depressor that are regulated by genetic sex and by

269 More than half of the anal swabs did not contain all causative HPV types.

270 II or III rectal cancer within 12 cm of the anal verge were randomized after completion of neoadjuva

271 T3 rectal adenocarcinoma within 12 cm of the anal verge with no evidence of metastasis.

272 ce of the rectum, located within 8 cm of the anal verge, and with an Eastern Cooperative Oncology Gro

273 ocarcinoma of the rectum within 15 cm of the anal verge, not invading adjacent tissues, and without d

274 and had a tumour located within 15 cm of the anal verge.

275 This demarcation is not dependent on the anal depressor's intrinsic genetic sex, but is influence

276 delivery of a therapeutic dose of PE to the anal sphincter muscle layer with less pain.

277 Domains and codes relevant to anal cancer treatment were selected from interviews to i

278 lysis to highlight discrepancies relevant to anal cancer.

279 on analysis of RNA-seq data, proper tools to anal.yze RNA-seq time-course have not been proposed.

280 Trans-anal irrigation (TAI) is used widely to treat bowel dysf

281 In men who have sex with men undergoing anal cytology and high-resolution anoscopy, we measured

282 1 prophylaxis among men who have unprotected anal sex with men.

283 being HIV uninfected, not having unprotected anal intercourse, older age, and being on highly active

284 I)(2) 0%-91%), and engagement in unprotected anal sex (OR = 1.72, 95% CI(OR) 1.44-2.05, I(2) = 0.0%,

285 The proportion of MSM reporting unprotected anal intercourse (UAI) in the past year increased from 4

286 luntary FHL contraction as well as voluntary anal sphincter contraction.

287 ic anal sphincter contraction, but voluntary anal sphincter contraction occurs without FHL contractio

288 dverse events, the most common of which were anal abscess (six in the Cx601 group vs nine in the plac

289 llomavirus (HPV) is causally associated with anal cancer, as HPV DNA is detected in up to 90% of anal

290 HPV genotyping alone and in combination with anal cytology.

291 The proportion of men with anal HPV of any type increased from 10.0% in men reporti

292 e in longitudinal follow-up of patients with anal cancer treated with (chemo)radiation, the EORTC-QLQ

293 However, patients with anal pain, anal lesions, and other high-risk factors are

294 e dysplasia were more likely to present with anal lesions on physical examination compared with patie

295 Forty-one patients (45%) presented with anal pain (odds ratio, 5.25; 95% CI, 1.44-21.82; P = .02

296 y-five HIV-infected women were screened with anal cytology.

297 a from women who underwent AC screening with anal cytology from April 2009 to July 2014 were analyzed

298 recommend routine anal cancer screening with anal cytology in persons living with human immunodeficie

299 85 of 86 patients were symptomatic with anal bleeding (78 %), anal/perianal pain (63 %), weight

300 for lung (difference in medians = 4 years), anal (difference = 4), oral cavity/pharynx (difference =